Express News | RemeGen Co Ltd: Safety Profile in Phase III Study of Disitamab Vedotin Was Consistent With Past Disitamab Vedotin Use Experience

ReutersDec 12 18:25 ET

Express News | RemeGen Co Ltd: Disitamab Vedotin Significantly Improved Progression-Free Survival Versus Lapatinib Plus Capecitabine

ReutersDec 12 18:24 ET

2024 SABCS|Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer With Liver Metastasis

PR NewswireDec 12 18:20 ET

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 8 23:10 ET

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8 03:48 ET

Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen

Yahoo FinanceDec 2 04:31 ET